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Abstract: Diet is the main environmental stimulus chronically impinging on the organism throughout
the entire life. Nutrients impact cells via a plethora of mechanisms including the regulation
of both protein post-translational modifications and gene expression. Palmitoylation is the
most-studied protein lipidation, which consists of the attachment of a molecule of palmitic acid
to residues of proteins. S-palmitoylation is a reversible cysteine modification finely regulated by
palmitoyl-transferases and acyl-thioesterases that is involved in the regulation of protein trafficking
and activity. Recently, several studies have demonstrated that diet-dependent molecules such as
insulin and fatty acids may affect protein palmitoylation. Here, we examine the role of protein
palmitoylation on the regulation of gene expression focusing on the impact of this modification on
the activity of chromatin remodeler enzymes, transcription factors, and nuclear proteins. We also
discuss how this physiological phenomenon may represent a pivotal mechanism underlying the
impact of diet and nutrient-dependent signals on human diseases.
Keywords: protein palmitoylation; nutrient-dependent signals; chromatin remodelers; transcription
factors; epigenetics; personalized medicine
1. Introduction
It is widely established that diet- and nutrient-related signals impinge on cell physiology and
play a pivotal role in the health/disease balance of human bodies [1]. Diet-derived molecules such as
insulin, glucose, and fatty acids (FA) influence cell signaling and regulate both enzyme activity and
gene expression through a plethora of only partially known mechanisms [2–4].
Carbohydrates and lipids are the main energy sources for cells and their catabolism produces
metabolic intermediates such as adenosine triphosphate (ATP) and acetyl-CoA, which are also
fundamental donor molecules for protein phosphorylation and acetylation, respectively [5,6].
Moreover, FA represent the substrate for protein acylation (also named protein lipidation), a group of
post-translational modifications (PTMs) including myristoylation, prenylation, and palmitoylation
(Figure 1). Protein lipidation dynamically regulates cell response to extrinsic and intrinsic
environmental cues [7,8], modulating protein stability and interaction, enzymatic activities, and protein
localization [9–13].
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Figure 1. Lipid modifications. Prenylation, myristoylation, and palmitoylation are the most relevant 
protein lipidation processes regulating the interaction of modified proteins with cellular membranes. 
Protein prenylation involves the transfer of either a farnesyl or a geranylgeranyl moiety to the 
C-terminal cysteine(s) (C, yellow) of the target protein. Myristoylation occurs on an N-terminal 
glycine (G, blue), while palmitoylation may target different amino acids including cysteine, serine (S, 
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protein lipidation processes regulating the interaction of odified proteins ith cellular e branes.
rotei re ylatio i volves t e tra sfer of eit er a far esyl or a gera ylgera yl oiety to t e
-ter i al cysteine(s) (C, yellow) of the target protein. Myristoylati n occurs on an N-terminal glycine
(G, blue), while palmitoylation m y target differ nt amino acids inclu ing cysteine, seri e (S, green),
or lysine (K, violet). a, aliphatic amino acid; M, methionine; X, undefined amino acid; T, threonine.
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In the following sections, we first summarize how FA and nutrient-dependent signals regulate
protein palmitoylation. Then, we discuss the mechanisms underlying gene expression modulation by
protein palmitoylation, with particular focus on nuclear proteins such as chromatin remodeler enzymes,
transcription factors, and histone proteins. An increasing body of evidence from experimental models
highlights the role of environmental epigenetics in disease susceptibility [14]. An intriguing hypothesis
is that aberrant palmitoylation might represent a mechanism underlying the effects of metabolic stress
on human diseases. The role of protein palmitoylation in cancer and neurological diseases will be
also discussed.
2. Biochemistry of Palmitoylation and Biological Functions
Protein acylation consists in the binding of saturated or unsaturated FA to glycine, serine, lysine,
or cysteine residues of proteins. The number of carbons in the fatty acid substrate determines the
kind of fatty acylation. The main protein acylations occurring in cells are myristoylation, prenylation,
and palmitoylation.
Myristoylation consists in the attachment of a molecule of myristate, a 14-carbon saturated fatty
acid, to N-terminal glycine residues via an irreversible amide linkage, catalyzed by the ubiquitous
eukaryotic enzyme N-myristoyltransferase (NMT) [15]. Point mutation experiments performed
in vitro on synthetic peptides resembling the N-terminal sequences of known N-myristoylated
proteins allowed the identification of the putative amino acid motif targeted by myristoylation
(Met–Gly–X–X–X–Ser/Thr) [16]. Recent studies suggested that many proteins are myristoylated
in human cells [17]. Typically, myristoylation facilitates the protein–membrane association that is
required for targeting proteins in specific organelles for their biological function.
Prenylation involves the addition of prenyl groups via a thioether bond to a cysteine residue
and is commonly considered an irreversible PTM [18]. Most prenylated proteins contain a conserved
CAAX motif at the C-terminus (C: cysteine; A: aliphatic amino acid; X: any amino acid), where the
consensus cysteine residue can be modified by the addition of farnesyl (15-carbon) or geranylgeranyl
(20-carbon) groups by two different enzymes, farnesyltransferase or geranylgeranyltransferase I,
respectively [19] (Figure 1). About 2% of eukaryotic proteins are supposed to be prenylated [20].
Interestingly, prenylation increments the hydrophobicity of the C-terminus of proteins, increasing their
capacity to interact with other proteins and cellular membranes [21,22].
Palmitoylation is the most studied fatty acylation, consisting in the attachment of a palmitic
acid (PA) molecule, a 16-carbon saturated FA, to proteins. Palmitoylation is the only reversible fatty
acylation finely modulated by a class of enzymes named palmitoyl acyltransferases (PATs) [23].
About 10% of the genome codifies for palmitoylable proteins, which all together constitute
the so-called “palmitoylome”. High-throughput screening using mass spectrometry has revealed
that human diseases including cancer, viral infections, and immunological and neurodegenerative
disorders are associated with severe alterations in the palmitoylome [24]. Moreover, recent studies
have demonstrated that nutrient-derived molecules such as insulin and fatty acids may critically
change protein palmitoylation [25,26].
Palmitoylation was first studied for its impact on protein trafficking between the plasma
membrane and the cytosol (or Golgi apparatus) but, over the years, several nuclear proteins have been
identified as targets of palmitoylation, suggesting a potential role of this acylation in the control of
gene expression.
Palmitoylation targets several proteins residues, including cysteine (S-palmitoylation or
N-palmitoylation when it occurs at the N-terminus of the protein) and serine (O-palmitoylation),
as illustrated in Figure 1. The most studied enzymatic reaction involving PA is S-palmitoylation,
in which PA is reversibly linked to cysteine residues using palmitoyl coenzyme A as a substrate [27]
(Figure 2).
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Finally, the epsilon-amino group of lysine has also been proposed as a possible target of 
palmitoylation [31]. 
PATs are characterized by four to six transmembrane domains and by the presence of a 
51-amino acid zinc finger-like domain including an aspartate-histidine-histidine-cysteine (DHHC) 
motif [32]. The highly conserved DHHC domain is inside the catalytic domain and mutations of this 
motif box impair the palmitoyl-transfer reaction [33]. 
To date, seven PATs (also named DHHC proteins) expressed in yeast [34,35] and 23 DHHC in 
mammalian cells have been discovered [36]. 
The biochemistry of palmytoilation is still not sufficiently understood, but it has been 
demonstrated that PAT enzymes catalyze the addition of palmitate to proteins via a two-step 
mechanism. First, they bind and hydrolyze the palmitoyl-CoA, forming a chemical intermediate 
between enzyme and palmitate. Subsequently, the acyl group is transferred to the target protein 
[32,37]. 
On the other side, acyl protein thioesterases catalyze the thioester hydrolysis of palmitoylated 
cysteines. These enzymes are usually localized in two cellular compartments: lysosomes, as the 
Palmitoyl-Protein Thioesterase 1 (PPT1), or the cytosol, such as acyl-protein thioesterase 1 (APT1) 
and 2 (APT2) [38,39]. Recently, the α/β-Hydrolase domain-containing protein 17  (ABHD17) family 
has been shown to remove palmitate from NRAS [40]. Notably, APT1 and APT2 inhibition reduces 
palmitate turnover on some proteins but has no effect on NRAS or postsynaptic density (PSD)-95. 
Similarly, the overexpression of ABHD16A, ABHD6, or APT1/2 had a weak effect on NRAS and 
PSD-95 depalmitoylation. However, the expression of ABHD17A, ABHD17B, or ABHD17C 
Figure 2. Protein S-palmitoylation biochemistry. Protein S-palmitoylation is a reversible modification
dynamically regulated by palmitoyl acyltransferases, which add a molecule of palmitic acid to proteins,
and acylthioesterases, which catalyze protein deacylation by removing the acyl moiety.
Conversely, both O-palmitoylation and N-palmitoylation appear to be irreversible [28–30]. Finally,
the epsilon-amino group of lysine has also been proposed as a possible target of palmitoylation [31].
PATs are characterized by four to six transmembrane domains and by the presence of a 51-amino
acid zinc finger-like domain including an aspartate-histidine-histidine-cysteine (DHHC) motif [32].
The highly conserved DHHC domain is inside the catalytic domain and mutations of this motif box
impair the palmitoyl-transfer reaction [33].
To date, seven PATs (also named DHHC proteins) expressed in yeast [34,35] and 23 DHHC in
mammalian cells have been discovered [36].
The biochemistry of palmytoilation is still not sufficiently understood, but it has been
demonstrated that PAT enzymes catalyze the addition of palmitate to proteins via a two-step
mechanism. First, they bind and hydrolyze the palmitoyl-CoA, forming a chemical intermediate
between enzyme and palmitate. Subsequently, the acyl group is transferred to the target protein [32,37].
On the other side, acyl protein thioesterases catalyze the thioester hydrolysis of palmitoylated
cysteines. These enzymes are usually localized in two cell lar compartments: lysosomes, as the
Palmitoyl-Protein Thioesterase 1 (PPT1), or the cytosol, such as acyl-protein thioesterase 1 (APT1)
and 2 (APT2) [38,39]. Recently, th α/β-Hydrola e domain-containing protein 17 (ABHD17) family
has b en hown to remove palmitate from NRAS [40]. Notably, APT1 and APT2 inhibition reduc s
palmitate turnover on some proteins but has no effect on NRAS or postsy aptic density (PSD)-95.
Similarly, the overexpression of ABHD16A, ABHD6, or APT1/2 had a weak effect on NRAS and
PSD-95 depalmitoylation. However, he expression of ABHD17A, BHD17B, or ABHD17C accelerat d
the hydrolysis of palmitate. These data have also been c firmed by ABHD17A/B/C knockdown in
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human embryonic kidney 293T cells since NRAS palmitate turnover was strongly inhibited when all
three ABHD17 proteins were simultaneously silenced [40].
Cycles of protein palmitoylation/depalmitoylation are essential for the modulation of many
aspects of cell physiology. Moreover, the development of click chemistry-based FA probes has revealed
the dynamic processes underlying several signaling pathways [41,42]. For instance, palmitoylation
of the tyrosine kinase Lck induces the recruitment of the enzyme to the plasma membrane and is
essential for the activation of T cell receptor signaling in human T lymphocytes [43]. Furthermore,
the glutamate receptor activation-dependent turnover of PSD-95 palmitoylation is fundamental for the
modulation of synaptic strength and plasticity in neurons [44].
Cycles of acylation and deacylation are also required for the plasma membrane association
of RAS-family and guanine nucleotide-binding (G) proteins. The pharmacological inhibition of
thioesterases is able to block RAS trafficking and repress RAS oncogenic activity [45].
Actually, the S-palmitoylated proteins lack a specific sequence motif. This peculiarity makes
it difficult to predict which proteins will undergo this PTM and, therefore, requires empirical
identification. In this regard, the proteomic approach has highlighted an increasing number of
identified palmitoylated proteins, opening up many exciting avenues for research [46].
3. Nutrient-Dependent Regulation of Protein Palmitoylation
Diet-derived molecules can impact cell physiology through multiple mechanisms including the
regulation of both protein PTM and gene expression [1,3,4]. Recently, several studies have highlighted
how nutrient-dependent signals may influence metabolism by changing protein palmitoylation in
several tissues. Insulin is the most important hormone controlling both carbohydrate and lipid
metabolism. The main mechanism by which insulin regulates glucose uptake and energy storage
involves the exposure of glucose transporter (GLUT) 4 on the plasma membrane surface [47].
The cellular localization of GLUT4 is governed by a finely regulated process of vesicle recycling [48].
This glucose transporter is predominantly expressed in adipose and muscle tissues and plays
a critical role in the maintenance of glucose homeostasis and peripheral insulin sensitivity [49].
During fasting, GLUT4 is mainly maintained in intracellular compartments, but postprandial insulin
stimulation promotes its translocation to the plasma membrane via the palmitoylation of cysteine
233 [50]. Accordingly, the deletion of DHHC7, the main PAT involved in GLUT4 palmitoylation,
induces hyperglycemia and glucose intolerance in mice [51]. More generally, insulin can affect the
palmitoylation of more than 300 proteins in human endothelial cells and defects of palmitoylation
affect endothelial cell migration [52].
Proteomic analyses in adipocytes revealed a wide range of palmitoylated proteins including those
involved in GLUT4 membrane translocation (e.g., insulin-regulated aminopeptidase) and the Janus
kinase/signal transducers and activators of transcription (JAK/STAT) pathway (e.g., JAK1 and 2;
STAT1, 3, and 5A; Src homology- 2 domain containing phosphatase) [53]. This study also showed
that the palmitoylation of GLUT4, IRAP, and JAK1 plays a regulatory role in adipose function and is
impaired in obesity and insulin resistance.
In line with these observations, we demonstrated that feeding mice with a high-fat diet (HFD)
increased the deposition of PA and altered insulin signaling in the hippocampus [26]. The insulin
desensitization in the brain led to DHHC3 overexpression via FoxO3a activation that, together with PA
accumulation, induced the hyper-palmitoylation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) glutamate receptor subunit GluA1. These molecular changes were responsible for the
synaptic plasticity impairment and cognitive deficits observed in HFD-fed mice. The critical role of
aberrant GluA1 palmitoylation in the HFD-related alteration of synaptic plasticity was confirmed
through the overexpression of palmitoylation-deficient GluA1 and the hippocampus-specific silencing
of Zdhhc3. Both experimental approaches prevented the impairment of synaptic plasticity and cognitive
deficits in HFD-fed mice. Interestingly, the intranasal delivery of the palmitoyltransferase inhibitor
2-Bromopalmitate (2-BP) restored normal levels of GluA1 palmitoylation in the hippocampus and
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counteracted the impairment of learning and memory in HFD-fed mice [26]. This was the first evidence
that the alteration of insulin signaling may impinge on the palmitoylation of neuronal proteins.
Moreover, our findings revealed that preventing aberrant protein palmitoylation may counteract the
brain insulin resistance-dependent impairment of synaptic plasticity.
The tight relationship between lipid metabolism and protein palmitoylation is also indicated by the
high S-depalmitoylation activity detected in the mitochondria of mammalian cells [54]. These findings
confirm that palmitoylation may occur in cellular compartments other than the cytosol and Golgi
apparatus and suggest a role of this PTM in the regulation of mitochondrial lipid homeostasis.
Accordingly, it has been demonstrated that the palmitoylation of the FA translocase CD36 modulates
both its localization and activity [55]. Moreover, increased CD36 palmitoylation was observed in livers
of mice with non-alcoholic fatty liver disease (NASH) [53] and was directly related to intracellular
lipid accumulation in human liver biopsies obtained from patients with NASH [56].
Finally, protein palmitoylation is also modulated by glucose concentration in rat pancreatic
islets [57]. Specifically, protein S-depalmitoylation is involved in glucose-dependent insulin
secretion in β-cells [58]. Accordingly, signaling pathways inducing insulin secretion in β-cells
involve numerous protein targets for acylation including receptors [59], ion channels [60,61],
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins [62],
and G-proteins [63].
In summary, nutrient-related molecules may affect the palmitoylation of numerous proteins in
different organs and cell types. Palmitoylated proteins have been mainly described in the cytosol
and Golgi apparatus, although several targets have been identified in all intracellular organelles.
Therefore, protein palmitoylation may represent a novel signal transduction mechanism underlying
the effect of metabolic stimuli on cell physiology. Considering the pivotal role of this post-translational
modification in regulating both the localization and activity of targeted proteins, emerging interest is
turning to the palmitoylation of nuclear proteins in the regulation of gene expression.
4. Palmitoylation of Transcription Factors
Lipid modifications increase the proteins’ hydrophobicity and thus their tendency to associate
with membranes. This may facilitate the proteins’ propensity to anchor any membranes and, in the
case of transcription factors, to reach the nucleus.
This scenario occurs for all sex steroid receptors (SR), such as estrogen, progesterone,
and androgen receptors, which have a highly conserved palmitoylation motif of nine amino acids [64].
Estrogen receptor (ER) α, the most characterized among the palmitoylated SR, translocates from the
plasma membrane to the nucleus upon de-S-palmitoylation [65]. Proteomic studies showed that the
heat shock protein 27 (Hsp27) impinges on ERα palmitoylation by promoting its interaction with
the acyl transferase DHHC7 and/or DHHC21 [66]. The palmitoylation of ERα induces its binding
to Caveolin-1 [67], followed by localization in lipid rafts [66] and the activation of steroid signaling
leading to DNA transcription [68]. The critical role of palmitoylation in steroid signaling has been
demonstrated by the transgenic mouse model of palmitoylation-deficient ERα. These animals showed
fertility impairment, veins vasodilation, and endothelial repair due to the loss of receptor localization
to the membrane and diminished estrogen pathway activation [69].
Recent studies have also identified the TEA domain transcription factor family (TEAD1-4) as
targets of S-palmitoylation [70]. TEAD is known as a transcriptional effector of the Hippo signaling
pathway, which is involved in tissue homeostasis, proliferation, and cell growth. TEADs contain three
evolutionarily conserved cysteine residues (C53S, C327S, and C359S), which are palmitoylated without
affecting the localization of the transcription factors [71]. Crystallography revealed that the palmitoyl
group is located inside a hydrophobic pocket of TEAD2 [71]. Palmitoylation regulates the protein
stability of TEADs, facilitating their interaction with the transcription co-activators Yes-associated
protein (YAP) and Tafazzin (TAZ) [71]. Once activated, TEADs co-localize with YAP/TAZ in the
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nucleus. ChiP-seq experiments pointed out that both transcription factors co-localize on the enhancer
regions of DNA [72].
Moreover, the palmitoylation of TEADs on three cysteine residues occurs in vitro even in
PAT-free conditions, suggesting that these transcription factors may undergo enzyme-independent
autopalmitoylation [70,73]. However, in vivo TEAD palmitoylation may require specific enzymes
because bacterially expressed TEAD is not efficiently palmitoylated [71]. A more in-depth knowledge
of the functional role of TEAD palmitoylation would be very important considering the implications
of the Hippo signaling pathway in cell proliferation and cancer.
The palmitoylation of transcription factors also plays a critical role in stress-dependent gene
activation [73]. In plants, the palmitoylation of the transcription factor MfNACsa, a member of the
NAM, ATAF1/2, and CUC2 (NAC) family, regulates its localization and is part of an orchestrated
signaling cascade leading to drought tolerance. In particular, S-palmitoylation anchors MfNACsa
to the plasma membrane, whereas under drought stress MfNACsa is de-S-palmitoyled by the
thioesterase APT1 and translocates to the nucleus [74]. Similarly, the fatty acylation of nuclear factor
of activated T cells 5α (NFAT5a) affects its nuclear import and modulates high salt stress-mediated
transcriptional activity in mammals [75]. Since changes of protein palmitoylation may occur in
response to metabolic stress [76], it would be interesting to deepen the knowledge of the transcription
factors whose localization and interaction with the regulatory sequences can be influenced by this
post-translational modification.
5. Palmitoylation of Chromatin Remodelers and Histone Proteins
Gene expression is finely modulated through both the transcription factor activity and
the chromatin organization [77]. Chromatin remodelers (e.g., enzymes regulating acetylation
and/or methylation of histone proteins) influence the assembly of transcriptional machinery by
inducing histone post-translational modifications changing the DNA architecture [78]. Moreover,
chromatin remodelers undergo enzymatic modifications regulating their activity and localization [79].
The S-palmitoylation of histone acetyltransferase p300 is required for its accumulation at the nuclear
compartment, since cell treatment with 2-BP inhibits the differentiation of neuronal cells by blocking
the nuclear import of p300 [80].
The switch from self-renewal to the differentiation of neural stem cells is also modulated by the
S-palmitoylation of the adenovirus early region 1A (E1A)-like inhibitor of differentiation 1 (EID1).
Indeed, the inhibition of EID1 palmitoylation reduces its proteasome-dependent degradation and
promotes its interaction with CREB-binding protein (CBP)/p300 complex, leading to decreased histone
acetyltransferases activity and the suppression of differentiation genes [81].
Recently, it has been demonstrated that sirtuins, which are members of a highly conserved
family of nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylases, catalyze the
hydrolysis of long-chain fatty acyl groups from the lysine residues of proteins [82,83]. The first sirtuin
discovered with the ability of removing long-chain fatty acyl groups was Plasmodium falciparum Sir2A
(PfSir2A). The structure of PfSir2A revealed that this sirtuin has a hydrophobic pocket that allows
interaction with the acyl group of proteins [84]. The ability of sirtuins (SIRT) to remove hydrophobic
acyl modifications seems to also be conserved in mammalians. SIRT1, SIRT2, SIRT3, and SIRT6
contain a hydrophobic pocket similarly to PfSir2A, indicating that the de-fatty acylation activity is
maintained among different species [82,83,85]. The de-fatty acylation activity of SIRT6 has been
shown to regulate tumor necrosis factor α (TNFα) secretion [83] and RAS2/phosphatidylinositol
3-kinase (PI3K) signaling [86]. These studies highlighted the role of lysine fatty acylation in the
control of protein–protein interactions. Considering the nuclear localization of SIRT1 and SIRT6 [87],
the emerging the de-acylating activity of sirtuins lays the foundations for a potential novel mechanism
of gene expression regulation.
Accordingly, proteomic analysis in mammalian cells revealed that several variants of histone H3
were S-palmitoylated at cysteine 110 [88]. However, the functional role of H3 palmitoylation is still
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unclear, as it might modulate the stability of the H3/H4 tetramer or modify the interaction between
chromatin and the nuclear membrane. In addition, Zou et al. found that, upon calcium stimulation,
the enzyme acyl-CoA:lysophosphatidylcholine acyltransferase (Lpcat1) catalyzed the palmitoylation of
serine 47 on histone H4 (O-palmitoylation) [89]. Interestingly, this modification was found to regulate
RNA polymerase II activity and to activate transcription [89].
However, the effects of palmitoylation on chromatin organization are not limited to histone
proteins. A recent study performed in Saccharomyces cerevisiae showed that palmitoyltransferase
Pfa4 is implicated in heterochromatin formation via the palmitoylation of the telomere-binding
protein Rif1 [90]. The telomeres, which contain domains of heterochromatin, are bound to a fibrillar
network known as the nuclear lamina. The authors found that, upon palmitoylation, Rif1 reduced the
silencing of chromatin by competing with Silent Information Regulator/Repressor Activator Protein 1
(SIR/RAP1) complex for telomeric DNA binding. Thereby, Rif1palmitoylation may influence telomere
anchoring, nuclear organization, and heterochromatin silencing [91]. Collectively, experimental
evidence indicates that protein palmitoylation can be modulated by metabolic signals and may
represent a novel mechanism regulating chromatin structure and gene expression. Considering
both the well-established role of aberrant palmitoylation in cancer and the emerging interest toward
protein palmitoylation in neurological diseases, the following sections focus on palmitoylation targets
potentially linking altered metabolic signals and human diseases.
6. Palmitoylation and Cancer
Protein S-palmitoylation is implicated in a plethora of cellular mechanisms underlying the control
of homeostasis in human physiology, and inappropriate regulation of this PTM results in the aberrant
activation of different signaling cascades potentially involved in human diseases. The aberrant
activation of PATs has been reported in a wide variety of human cancers [92]. Palmitoylated
proteins include enzymes regulating proliferation, apoptosis, angiogenesis, and invasiveness [92].
Cross-referencing of a list of cancer driver genes with the results of palmitoylome studies suggests that
26% of the encoded proteins may be palmitoylated, highlighting the implication of this modification
in cancer development [93]. The most studied palmitoylated protein, among those associated with
cancer, is the guanosine triphosphate hydrolase (GTPase) RAS family [94]. Aberrant activation of the
oncogene RAS, due to the defective regulation of palmitoylation, is present in up to 30% of cancer
cases, resulting in uncontrolled cell growth and proliferation [95]. In vivo, anomalous processing of
NRAS palmitoylation, a protein of the RAS family, is involved in leukemogenesis. Specifically, bone
marrow cells transplanted in a mouse model are incapable of inducing cancer if they are transfected
with the palmitoylation-deficient NRAS mutant [96]. The inhibition of NRAS palmitoylation prevents
its normal membrane localization and hyper-activation of its downstream signaling effectors (Erk, Akt,
Raf, and Ral) [96], demonstrating that oncogenic NRAS signaling requires palmitoylation-dependent
membrane localization. The palmitoylation of both NRAS and H-RAS occurs in the Golgi compartment,
and this PTM is regulated by a complex of PATs formed by zinc finger DHHC domain containing
(ZDHHC)9 and Golgin (GOLG)A7 [97]. In mice lacking Zdhhc9, both NRAS-mediated T-cell acute
lymphocytic leukemia and chronic myelomonocytic leukemia are significantly attenuated but not
completely prevented. This incomplete phenotypic suppression implicates the action of multiple
PATs to palmitoylate NRAS in vivo [98]. The involvement of several PATs in the control of the
RAS family activity hinders the development of a pharmacology strategy against RAS-dependent
cancer progression.
In recent years, it has become well known that dysregulation of the Hippo pathway results in a
cancerous phenotype. Aberrant Hippo signaling is induced by mutations or altered expression levels
and activity of several Hippo pathway components [99]. Equally, deactivation of the Hippo pathway
impinges on cell growth and tumors [100]. A further instance of aberrant palmitoylation-dependent
control over cancer-associated proteins is provided by Scribble (SCRIB), which is implicated in the
Hippo pathway. SCRIB is a tumor-suppressor protein that regulates epithelial cell polarity [101,102].
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Hippo kinase cascade is inactivated by the loss of SCRIB, leading to the accumulation of YAP and
TAZ in the nucleus, and the activation of the mitogen-activated protein kinase (MAPK) and protein
kinase B (AKT) pathways [103–105]. Once palmitoylated, SCRIB is stabilized in the membrane,
where activates the Hippo kinase cascade and represses MAPK and AKT signaling [103,104].
DHHC7 has been identified, through co-immunoprecipitation (co-IP) experiments, as a primary
SCRIB palmitoyltransferase [103]. Interestingly, knockout of DHHC7 led to a SCRIB mislocalization
through the loss of palmitoylation and increased YAP nuclear localization and activation, causing a
switch of SCRIB function from tumor-suppressor to oncoprotein [103]. Moreover, enhancing SCRIB
palmitoylation by the inhibition of thioesterases caused an increase of SCRIB stability in the membrane,
resulting in a decrease of tumorigenicity [104].
Another important palmitoylated factor involved in the Hippo pathway is TEADs, which have
been found to be overexpressed in different types of tumors [106–109]. High TEAD expression
levels have been observed in colorectal, breast, and prostate cancers [109]. In breast cancer cells,
an upregulation of TEAD2 and a marked increase in YAP/TAZ nuclear accumulation have been
observed in spite of the overall reduction of YAP/TAZ protein levels [110]. The increased expression
TEAD2 resulted in an augmented binding of YAP/TAZ complex, which was retained in the nucleus
leading TEAD transcriptional activity. Higher levels of TEAD2 and TEAD4 were also found in
colorectal cancer, specifically in metastatic tissues, and experiments performed in vivo and in vitro
have shown that knockdown of TEAD4 reduces metastasis and cell migration [109].
TEAD levels are a useful prognostic marker in cancer, and their modulation could be helpful to
develop a strategy against cancer progression. In a transgenic mouse model of liver cancer mediated by
YAP overexpression, transfection with a mutant TEAD lacking the DNA binding domain counteracted
the YAP-induced tumor [111].
Because of the relevant roles that TEADs plays in cancer development and progression,
TEAD proteins are being considered as promising therapeutic targets for antagonizing Hippo
transcription under oncogenic conditions. Furthermore, a new strategy could be the development
of compounds targeting the TEAD hydrophobic pocket. However, the specific acyl-transferase
modulating the Hippo pathway and the target-specific effect of aberrant palmitoylation in tumor
growth and invasiveness remain to be understood.
Using both computational and experimental approaches, a recent study showed that flufenamate
(a nonsteroidal anti-inflammatory drug) binds a lipid pocket and inhibits TEAD transcriptional
activity without disrupting YAP–TEAD interaction, but leads to decreased cell proliferation and
migration [112]. Since flufenamate binds the hydrophobic pocket of TEAD, which is the portion where
palmitoylation occurs, this drug may counteract cancer development and inhibit TEAD activity by
preventing its palmitoylation.
7. Palmitoylation and Neurodegenerative Diseases
Palmitoylation is implicated in a series of pathologies beyond cancer, involving processes not fully
understood yet. Currently, emerging evidence points to the role of aberrant palmitoylation in the onset
of several neurodegenerative disorders such as Parkinson′s, Huntington (HD), and Alzheimer′s (AD)
disease [113]. For instance, the dysfunction of D2 dopamine receptor (D2R), a G protein-coupled
receptor (GPCR) crucial for the regulation of mood, reward, motor control, and cognition, is linked to
schizophrenia and Parkinson’s disease [114,115]. Mutagenesis studies on D2R have identified Cys 443
as palmitoylation site required for plasma membrane-retention and protein stability of receptors [116].
The aberrant palmitoylation of D2R leads to dopamine dysregulation syndrome.
HD is an adult-onset neurodegenerative pathology characterized by progressive cognitive decline,
motor dysfunction, and psychiatric deficit [117,118]. HD is an autosomal dominant disease caused by
a mutation in the Huntingtin gene due to an expansion of the CAG trinucleotide repeat to more than
35 repeats, leading to an abnormal huntingtin protein (HTT) with an expanded polyglutamine in its
N-terminal domain, and toxic gain of function.
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HTT protein is palmitoylated at cysteine 214 (C214) by DHHC17 (also named HIP14) and DHHC13.
However, upon HD mutation, the interaction between HTT and its PATs is impaired, resulting in
a strong reduction of HTT palmitoylation [119,120]. It has also been demonstrated that HTT may
act as a modulator of DHHC17 activity, because the activity of palmitoyl-transferase appears to be
compromised upon HD mutation [121]. Consequently, PAT substrates are less palmitoylated, leading to
neuronal toxicity. These evidences suggest that altered interactions between PATs and mutant HTT
reduce palmitoylation and promote the mislocalization of HTT and other PAT substrates [121].
A recent study provided evidence on the involvement of palmitoylation in AD pathogenesis by
proving that amyloid precursor protein (APP) is palmitoylated in vitro and in vivo, and this PTM
regulates the amyloidogenic process [122]. AD is the most common form of neurodegenerative
disorders characterized by the accumulation of the β-amyloid peptide (Aβ) within the brain, leading
to neuronal dysfunctions, cognitive decline, and progressive memory loss [123,124]. Aβ peptide
is generated by the sequential proteolysis of APP, and it is widely recognized that this is the
crucial step in the development of AD [124]. APP is palmitoylated at C186 and C187 in the
N-terminal region and regulates the trafficking of APP to the membrane, since palmitoylation-deficient
APP mutants are retained in the endoplasmic reticulum. APP is palmitoylated by DHHC7 and
DHHC21, and overexpression of this PAT leads to an increase of Aβ production as well as APP
palmitoylation [122].
Furthermore, it has also been reported that the neuron-specific membrane-associated
amyloid-precursor protein-cleaving enzyme 1 (BACE1) may be palmitoylated in several cysteine
residues (C478, C474, C482, C485) by different PATs (DHHC3, DHHC4, DHHC7, DHHC15,
and DHHC20) [125,126]. Therefore, the aberrant palmitoylation of BACE1 might promote
the localization of secretase within lipid rafts and increase Aβ production [127]. Actually,
APP metabolism was not affected by palmitoylation-deficient BACE1 mutants, thus indicating that
BACE1 palmitoylation is not involved in Aβ production [128]. Strikingly, drugs inhibiting PAT activity
decreased Aβ production, supporting the hypothesis that the palmitoylation of enzymes involved in
Aβ production would be required for Aβ accumulation [129,130]. However, to date, the role of protein
palmitoylation in AD onset and progression has still not been completely clarified. More importantly,
aberrant palmitoylation might also influence neurodegeneration by targeting proteins other than APP,
BACE1, and the canonical Aβ synthesis pathway.
For instance, estrogens have a wide range of beneficial actions in brain and other tissues, and
alterations of the molecular pathways downstream from ER activation may increase the risk of AD [131].
An altered distribution of ERs has been observed in postmortem brains fromAD patients [132].
Furthermore, changes of ER localization from the nucleus to the cytoplasm inhibit the onset of AD in
transgenic mice and in humans [133,134]. Studies of endogenous sex steroids depletion in wild-type
female rodents have shown a significant increase of levels of soluble Aβ in the brain [135]. Furthermore,
ovariectomies in numerous transgenic mouse models of AD result in the significant acceleration of
Aβ pathology and the worsening of behavioral performance [136]. Moreover, female rodents treated
with 17β-estradiol exhibit significantly lower Aβ accumulation as compared to females treated with a
vehicle [137].
Several evidences link chromatin remodelers including sirtuins, CBP/P300, and EID1 to
neurodegenerative disorders. The sirtuin pathways are strongly compromised in dementia, since a
reduction of SIRT1 and SIRT3 protein levels have been observed in the AD brain. [138]. Also, in mouse
models of APP and presenilin 1 overexpression, the reduction of SIRT3 has been observed [139].
The modulation of SIRT1 by activation or overexpression interferes with Aβ toxicity through its
capacity to inhibit nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling [140].
Besides, CBP and P300 are mechanistically involved in the formation of amyloid-like aggregates [141]
and the depletion of CBP/P300 is linked to neurodegenerative diseases [142].
SIRT1 also contributes to the pathogenesis of AD via the accumulation of the microtubule-
associated protein tau. In the AD brain, tau is hyper-phosphorylated (p-tau) and forms neurofibrillary
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tangles. The acetylation of tau contributes to the accumulation of p-tau and the downregulation of
SIRT1 increases the acetylation of tau [143] mediated by acetyltransferase p300.
Moreover, the nuclear translocation of EID1 is increased in neurons of AD brains, and EID1
overexpression in mice increments its nuclear translocation, impairing long-term potentiation
(LTP) and memory. Moreover, the overexpression of EID1 results in the inhibition of CBP/p300
acetyltransferase activity and disrupts the neuronal structure, altering III-tubulin [144].
The abovementioned proteins have a role in the onset and development of neurological diseases,
and, interestingly, these pathways are modulated by palmitoylation.
In recent years, an increasing number of studies have focused on the correlation between dementia
and metabolic disorders such as obesity, insulin resistance, and type 2 diabetes (T2D). T2D induced the
development of amyloid plaques similar to non-diabetic AD, while the pharmacological treatment
of T2D reduced amyloid plaques compared to non-diabetics with similar levels of dementia [145].
Furthermore, obese patients show deficits in learning and memory as AD patients.
As discussed above, recent studies have demonstrated that diet-dependent signals may affect
protein palmitoylation in different tissues, including brain areas regulating learning and memory.
Moreover, restoring aberrant palmitoylation has been demonstrated to counteract brain insulin
resistance-dependent cognitive decline. Based on these premises, protein palmitoylation may be
a potential link between metabolic and neurodegenerative diseases. However, the lack of a specific
sequence motif and the absence of a robust enrichment method hinders a more accurate understanding
of palmitoylation and its regulation. Therefore, an important point is to develop high-throughput
dedicated methods to study palmitoylation. The proteomic approach paired with the development
of new and reliable methodologies for the recognition of palmitoylated proteins will facilitate the
comprehension of the role of palmitoylation in biological functions as well as its impact on the nuclear
compartment and gene regulation.
8. Conclusion and Future Perspectives
Emerging evidence indicates that protein palmitoylation is modulated by nutrient-dependent
signals and may impact the regulation of gene expression. Palmitoylation plays a pivotal role in
enzymatic activation and trafficking to the nucleus of proteins critically involved in chromatin
organization. The idea that diet-derived molecules may directly change the chromatin architecture,
as well as influence both gene activation and repression, opens the way to the study of novel
mechanisms underlying the gene–environment interaction. Finally, aberrant palmitoylation has
been linked to many human diseases including cancer, neurodegenerative diseases, and metabolic
disorders [13,76,146]. Future studies revealing the impact of nutrients on protein palmitoylation
will probably add novel layers to the knowledge on the link between nutrigenomics and
age-related diseases.
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